C4 Therapeutics: Cemsidomide Data Could Redefine What Counts as Progress in Myeloma

C4 Therapeutics Inc (CCCC) is scheduled to report second-quarter 2026 earnings on August 13, 2026. With the stock trading at $3.90 and analysts expecting a loss of $-0.21 per share, investors will be watching closely to see whether the biotech can continue its recent streak of earnings beats. The report comes at a pivotal moment as the company navigates its drug development pipeline and collaboration agreements while managing cash burn expectations.

Part 1: Earnings Preview

C4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other diseases. The company leverages its proprietary TORPEDO platform to design small-molecule drugs that selectively degrade disease-causing proteins.

CCCC is expected to report second-quarter results on August 13, 2026, with analysts projecting a loss of $-0.21 per share on revenue estimates that remain limited given the company's clinical-stage status. The company most recently reported second-quarter 2026 earnings of $-0.18 per share, beating estimates by 21.74%. Compared to the same quarter last year (Q2 2025), when CCCC posted a loss of $-0.44 per share, the current estimate of $-0.21 represents a 52.27% improvement year-over-year, signaling meaningful progress in the company's financial trajectory.

Three key themes define this earnings story:

Pipeline Progress and Clinical Milestones: Investors will scrutinize updates on C4's lead programs and any advancement through clinical trial stages. Recent collaboration agreements, including the April 2026 deal with Roche, have elevated expectations for partnership-driven validation of the company's platform technology.

Cash Runway and Burn Rate: As a clinical-stage biotech with no approved products, C4's quarterly cash consumption and remaining runway are critical metrics. Any guidance on extending the cash runway through partnerships, non-dilutive funding, or operational efficiencies will be closely watched.

Revenue from Collaborations: While product revenue remains years away, milestone payments and research funding from partnerships like Roche could provide meaningful near-term revenue beats, as evidenced by the $11.02 million revenue surprise in Q4 2025 that more than doubled estimates.

Analysts remain constructive heading into the print, with the company's track record of four consecutive earnings beats supporting expectations for another positive surprise. The focus will be on whether management can demonstrate continued progress in reducing losses while advancing its pipeline without excessive dilution.

Part 2: Historical Earnings Performance

C4 Therapeutics has established a strong pattern of exceeding analyst expectations over the past four quarters. The company beat estimates in Q2 2025 (+6.38%), Q4 2025 (+58.14%), Q1 2026 (+4.76%), and most recently Q2 2026 (+21.74%). The magnitude of these beats has been particularly impressive, with the Q4 2025 result representing a massive surprise where CCCC reported a loss of just $-0.18 versus expectations of $-0.43.

The trend shows meaningful improvement in the company's loss profile. Reported losses have compressed from $-0.44 in Q2 2025 to $-0.18 in Q2 2026, demonstrating either improved operational efficiency, partnership revenue, or both. The consistency of beats—four quarters in a row—suggests management may be effectively managing expectations or that the business is genuinely outperforming analyst models.

This track record sets a high bar for the upcoming Q3 2026 report. With analysts expecting $-0.21 per share, investors will likely anticipate another beat given the established pattern, making the stakes higher if the company merely meets or misses expectations.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Based on historical reporting patterns, C4 Therapeutics typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

C4 Therapeutics has exhibited volatile post-earnings price action with an average absolute Day 0 move of 5.58% and Day +1 move of 4.97%. The most dramatic reaction came in August 2025, when the stock surged 31.63% on Day 0 before giving back some gains. More recently, the May 2026 earnings triggered a substantial 16.09% Day +1 rally, suggesting positive momentum when results exceed expectations.

The trading ranges around earnings are wide, averaging 13.87% on Day 0 and 13.29% on Day +1, reflecting the high-beta nature of this clinical-stage biotech. Notably, the direction of moves has been mixed—while some reports sparked significant rallies, others like February 2026 saw modest declines despite beats. This suggests the market reacts more to pipeline updates and guidance than to the earnings beat itself, typical for pre-revenue biotechs where quarterly losses are expected.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 10.90% (±$0.43) for the upcoming earnings, which is below the stock's average historical Day 0 move of 13.87% but well above the recent trend of more muted reactions. This suggests options traders are anticipating meaningful volatility, though not at the extreme levels seen in some prior quarters.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on C4 Therapeutics, with the stock carrying an average recommendation of 4.75 out of 5.0—firmly in Strong Buy territory. The consensus includes 7 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 8 analysts covering the stock. This overwhelmingly positive view reflects confidence in the company's platform technology and pipeline potential.

The analyst sentiment has remained unchanged over the past month, indicating stable conviction despite the upcoming earnings event. The average price target of $13.33 implies substantial 242% upside from the current price of $3.90, with the high target of $30.00 suggesting some analysts see potential for even more dramatic appreciation. Even the most conservative target of $7.00 represents 79% upside, underscoring the broad belief that CCCC is significantly undervalued at current levels.

This wide range of targets ($7.00 to $30.00) reflects the inherent uncertainty in valuing clinical-stage biotechs, where outcomes are binary and dependent on trial results and regulatory approvals. However, the clustering of Strong Buy ratings suggests analysts view the risk-reward profile as favorable heading into this earnings report.

Part 4: Technical Picture

C4 Therapeutics enters earnings with improving technical momentum. The Barchart Technical Opinion currently shows a Buy signal at 64%, up from 40% last week but down from 80% last month, indicating some recent consolidation after a stronger bullish period.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum is cautiously positive but not overwhelming
• Medium-term (75% Buy): Strong buy signal indicates solid momentum in the intermediate timeframe as the stock builds on recent gains
• Long-term (100% Buy): Maximum buy signal reflects powerful strength in the longer-term trend, with the stock well above its 200-day moving average

Trend Characteristics: The combination of Good strength and Average direction suggests the stock is in a constructive uptrend but experiencing normal consolidation rather than parabolic momentum.

The stock is trading at $3.90, positioned above all key moving averages: the 5-day ($3.75), 10-day ($3.66), 20-day ($3.64), 50-day ($3.90), 100-day ($3.46), and 200-day ($2.91). This alignment with the stock above every major moving average is a classically bullish setup, indicating strong underlying support.

The 200-day moving average at $2.91 has provided a foundation for the stock's 34% rally year-to-date, while the recent test and hold of the 50-day moving average at $3.90 suggests near-term support is intact. The technical setup is supportive heading into earnings, with the stock in a confirmed uptrend across all timeframes. However, the high implied volatility of 110.15% and wide historical earnings ranges suggest investors should be prepared for significant post-announcement movement in either direction, making risk management essential for those holding positions through the print.